Gabriel M Galvin

Title: Innovations of Gabriel M Galvin

Introduction

Gabriel M Galvin is a notable inventor based in Maple Valley, WA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of dipeptidyl peptidase IV inhibitors. With a total of three patents to his name, his work has the potential to impact therapeutic approaches for various diseases.

Latest Patents

Gabriel's latest patents include a process for preparing a dipeptidyl peptidase IV inhibitor and the intermediates employed therein. This innovative process involves treating a specific structure with TFAA in isopropyl acetate to protect the tertiary hydroxyl group as a trifluoroacetate group. This results in the formation of a novel intermediate, which is then converted to an acid chloride compound using Vilsmeier reagent or other chloro reagents. The subsequent coupling with another compound in a heterogeneous mixture of ethyl acetate and aqueous bicarbonate leads to the creation of a new compound. The N,O-bis(trifluoroacetyl) groups of this compound are then deprotected to yield a free base compound.

Career Highlights

Gabriel M Galvin is currently employed at Bristol-Myers Squibb Company, where he continues to innovate in the pharmaceutical sector. His work is characterized by a commitment to advancing medical science through the development of new therapeutic agents.

Collaborations

Throughout his career, Gabriel has collaborated with esteemed colleagues such as Padam N Sharma and Edward J Gublo. These collaborations have likely contributed to the success of his innovative projects and patents.

Conclusion

Gabriel M Galvin's contributions to the field of pharmaceuticals through his patents and collaborations highlight his role as a significant inventor. His work in developing dipeptidyl peptidase IV inhibitors showcases the potential for innovation in medical treatments.